05:00 EDT Precigen (PGEN) jumps 32% to $2.44 after FDA approval of Papzimeos
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- FDA approves Precigen immunotherapy for respiratory papillomatosis
- Precigen trading halted, news pending
- Precigen’s Transformative Potential: Buy Rating Backed by Imminent FDA Decision and Strong Financial Outlook
- Precigen, Inc. Reports Q2 2025 Earnings and Strategic Focus
- Is PGEN a Buy, Before Earnings?